Navigation Links
HCA Announces Offering of $500 Million Senior Secured First Lien Notes
Date:4/14/2009

ans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, appeals and litigation associated with our tax positions, (21) potential liabilities and other claims that may be asserted against us, and (22) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2008 and other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE HCA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. RESOLVE: The National Infertility Association Announces Partnership With CutisPharma
2. PolicyStat Announces John C. Render has Joined company's Board of Advisors
3. Align Technology Announces ClearCorrects Filing of Notice of Voluntary Dismissal of Complaint
4. Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies
5. Dialysis Corporation of America Announces Share Repurchase Program
6. Misonix Announces New Distribution Agreement for Portugal
7. Medco Announces Date for First-Quarter 2009 Financial Results
8. Scotland Announces Establishment of Nurse-Family Partnership Program
9. Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion
10. Aladtec Inc Announces New Customers for Online Scheduling Systems -- First Quarter, 2009
11. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... 2007) Lower muscle mass and an increase in body ... exercise is a proven way to prevent the loss of ... Mark Tarnopolsky shows that taking a combination of creatine monohydrate ... exercise training provides even greater benefits. , The ...
... 2 Speaker Nancy Pelosi,released the following statement ... The Speaker was presented the National Breast,Cancer Coalition,s ... York City last,night: "National Breast Cancer Awareness ... and to recommit ourselves to advancing prevention, improving,treatments, ...
... imagine iPhones, laptops and flash drives. But more ... a newly updated inventory of nanotechnology consumer products ... and health products. , Maintained by the ... inventory includes Head NanoTitanium Tennis Racquets, Eddie Bauer ...
... is a statement,by Linda A. Suydam, D.P.A., president ... to inaccurate and misleading media reports,surrounding the U.S. ... Nonprescription Drugs Advisory Committee and Pediatric Advisory,Committee scheduled ... the makers of pediatric, over-the-counter cough and cold,medicines ...
... WASHINGTON, Oct. 2 Speaker Nancy Pelosi and,Senate Majority ... sending President Bush the Children,s Health Insurance,Program (CHIP) legislation:, ... a bipartisan bill,to insure 10 million of our nation,s ... American people that the President will sign the bill ...
... Offer Both Suspension and Tablet Forms, PRINCETON, N.J., ... subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL ... Administration (U.S. FDA) to manufacture and market Clarithromycin for,Oral ... Ranbaxy is the first,company to have been granted a ...
Cached Medicine News:Health News:Nanotechnology: not just for geeks 2Health News:Statement from the Consumer Healthcare Products Association on the Safety of Pediatric Over-the-Counter Medicines 2Health News:Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP 2
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... CeNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical ... the respected scientific,journal 'Synapse'* on its Phase II ... as a potential treatment for neuropathic,pain. The independent ... undertaken with CNS 5161. , In the study ...
... in Humans of CTI's,Programmable, Pulsatile, Passive Transdermal ... TRENTON, N.J., May 03, 2007 /PRNewswire/,-- Chrono ... of its first phase human clinical trial ... ChronoDose(TM). CTI intends to publish this,clinical data ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3
Suitable for mild to moderate ACL and/or PCL, MCL and LCL instabilities, this neoprene brace with extended hinge bars is an ideal intermediate-level product that can be used in sporting activities. C...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Provides comfortable compression, support and immobilization for the knee...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: